May 9, 2018
Stanley Falkow, PhD, FIDSA, passed away on Saturday, May 5, 2018 at his home in Portola Valley, California.
Read More
In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine.
Reviews in this issue: Mortality Benefit in Treating HCV-Infected Patients Without Advanced Liver Disease, Aerosolized and Oral Ribavirin for Respiratory Syncytial Virus Infection, and Back to the Basics: Hospital-Acquired Infections and Exposure to Other Sick Patients
In response to a member discussion on MyIDSA regarding IDSA’s journals, the use of plastic wrap and interest in an online-only option, IDSA will be holding a webinar May 15 at 4 p.m. EDT to discuss how we can work together to meet the needs of the Society and our members, while also protecting our natural resources.
Read More
The IDSA Telehealth and Emerging Technology Work Group has prepared a survey for our members to gain a better understanding of how telehealth technology is being used in the clinical practice of infectious diseases.
Read More
Are fellows at your institution interested in competing in the IDBugBowl? Well, this is their chance! Forward the link below so that they can apply for your institution to be one of the two national teams going up against two San Francisco teams at IDWeek 2018.
Read More
IDSA is continuing to advance our priorities as Congress moves forward on efforts to reauthorize the Pandemic and All Hazards Preparedness Act (PAHPA).
Read More
The Centers for Disease Control and Prevention (CDC) released their newest Morbidity and Mortality Weekly Report last week entitled “Vital Signs: Trends in Reported Vectorborne Disease Cases- United States and Territories, 2004-2016.”
Read More
Interested in engaging conversations related to the ID field? Open Forum Infectious Diseases (OFID) podcasts are now available on iTunes.
Read More
IDSA member, James Crowe, MD, FIDSA of Vanderbilt University spoke to Congressional staffers last week about the impact of US investments on the development of global health technologies and the returns on those investments.
Read More
IDSA member, James Crowe, MD, FIDSA of Vanderbilt University spoke to Congressional staffers last week about the impact of US investments on the development of global health technologies and the returns on those investments.
Read More
Share examples from your clinic or institution that will help us demonstrate to policymakers the implications of changes to the 340B Drug Discount Program.
Read More
The current draft of the Diagnostic Accuracy and Innovation Act (DAIA) contains prohibitive regulatory and budgetary implications for laboratory developed tests and threatens to wipe out many of the tests ID physicians use to manage some of the most seriously ill patients.
Read More
